Q-omics provides the consensus-scored SCGB1B2P profile across patient tissues and cancer cell-line models. SCGB1B2P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCGB1B2P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SCGB1B2P RNA expression shows 15,173 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where SCGB1B2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB1B2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB1B2P survival associations across molecular data types. SCGB1B2P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB1B2P RNA expression–survival associations across cancer types. High SCGB1B2P expression shows unfavorable associations in KIRC, UCEC and COAD, but favorable associations in UVM, BRCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SCGB1B2P RNA expression.
This table summarizes SCGB1B2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCGB1B2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB1B2P shows lower tumor expression in BRCA and LUAD and higher tumor expression in KIRC, LIHC, CHOL and KIRP. The KIRC box plot shows higher SCGB1B2P RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with SCGB1B2P in patient tissues and cancer cell lines. In patient samples, SCGB1B2P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
